Tazverik Dosage/Direction for Use

Patient Selection: Select patients with R/R FL for treatment with TAZVERIK based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Recommended Dosage: The recommended dosage of TAZVERIK is 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Swallow tablets whole. Do not cut, crush, or chew tablets.
Do not take an additional dose if a dose is missed or vomiting occurs after TAZVERIK, but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions: Table 2 summarizes the recommended dose reductions, and Table 3 summarizes the recommended dosage modifications of TAZVERIK for adverse reactions. (See Tables 2 and 3.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Dosage Modifications for Drug Interactions: Strong and Moderate CYP3A Inhibitors: Avoid co-administration of TAZVERIK with strong or moderate CYP3A inhibitors. If co-administration with a moderate CYP3A inhibitor cannot be avoided, reduce the TAZVERIK dose as shown in Table 4 as follows. After discontinuation of the moderate CYP3A inhibitor for 3 elimination half-lives, resume the TAZVERIK dose that was taken prior to initiating the inhibitor [see Effect of Other Drugs on TAZVERIK under Interactions; Pharmacology: Pharmacokinetics under Actions]. (See Table 4.)

Click on icon to see table/diagram/image